nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A43—Dexamethasone—multiple sclerosis	0.263	0.322	CbGbCtD
Ethosuximide—CYP2E1—Fingolimod—multiple sclerosis	0.152	0.186	CbGbCtD
Ethosuximide—CYP2E1—Mitoxantrone—multiple sclerosis	0.0713	0.0875	CbGbCtD
Ethosuximide—CYP3A4—Fingolimod—multiple sclerosis	0.046	0.0564	CbGbCtD
Ethosuximide—CYP3A7—Dexamethasone—multiple sclerosis	0.0383	0.047	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0383	0.047	CbGbCtD
Ethosuximide—CYP2E1—Dexamethasone—multiple sclerosis	0.037	0.0454	CbGbCtD
Ethosuximide—CYP3A4—Methylprednisolone—multiple sclerosis	0.0296	0.0363	CbGbCtD
Ethosuximide—CYP3A5—Dexamethasone—multiple sclerosis	0.0287	0.0353	CbGbCtD
Ethosuximide—CYP3A4—Triamcinolone—multiple sclerosis	0.0224	0.0275	CbGbCtD
Ethosuximide—CYP3A4—Mitoxantrone—multiple sclerosis	0.0216	0.0265	CbGbCtD
Ethosuximide—CYP3A4—Betamethasone—multiple sclerosis	0.0193	0.0236	CbGbCtD
Ethosuximide—CYP3A4—Prednisolone—multiple sclerosis	0.019	0.0233	CbGbCtD
Ethosuximide—CYP3A4—Prednisone—multiple sclerosis	0.0179	0.022	CbGbCtD
Ethosuximide—CYP3A4—Dexamethasone—multiple sclerosis	0.0112	0.0137	CbGbCtD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00185	0.0419	CbGpPWpGaD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00185	0.0419	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM1 interactions—PRNP—multiple sclerosis	0.00184	0.0415	CbGpPWpGaD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00183	0.0413	CbGpPWpGaD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00183	0.0413	CbGpPWpGaD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.0015	0.0339	CbGpPWpGaD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.0015	0.0339	CbGpPWpGaD
Ethosuximide—Pancytopenia—Cladribine—multiple sclerosis	0.00111	0.00784	CcSEcCtD
Ethosuximide—Rash erythematous—Betamethasone—multiple sclerosis	0.00109	0.00773	CcSEcCtD
Ethosuximide—Rash erythematous—Dexamethasone—multiple sclerosis	0.00109	0.00773	CcSEcCtD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—PRNP—multiple sclerosis	0.00108	0.0244	CbGpPWpGaD
Ethosuximide—Suicidal ideation—Prednisone—multiple sclerosis	0.00104	0.00736	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Cladribine—multiple sclerosis	0.00103	0.0073	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00101	0.00715	CcSEcCtD
Ethosuximide—Fatigue—Fingolimod—multiple sclerosis	0.00101	0.00714	CcSEcCtD
Ethosuximide—Hiccups—Prednisolone—multiple sclerosis	0.001	0.0071	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—CD24—multiple sclerosis	0.000939	0.0212	CbGpPWpGaD
Ethosuximide—Hiccups—Triamcinolone—multiple sclerosis	0.00092	0.00653	CcSEcCtD
Ethosuximide—Urinary tract disorder—Cladribine—multiple sclerosis	0.00092	0.00653	CcSEcCtD
Ethosuximide—Hiccups—Methylprednisolone—multiple sclerosis	0.000918	0.00651	CcSEcCtD
Ethosuximide—Connective tissue disorder—Cladribine—multiple sclerosis	0.000916	0.0065	CcSEcCtD
Ethosuximide—Urethral disorder—Cladribine—multiple sclerosis	0.000913	0.00648	CcSEcCtD
Ethosuximide—Abdominal discomfort—Azathioprine—multiple sclerosis	0.000908	0.00644	CcSEcCtD
Ethosuximide—Pancytopenia—Azathioprine—multiple sclerosis	0.000899	0.00638	CcSEcCtD
Ethosuximide—Erythema multiforme—Cladribine—multiple sclerosis	0.000881	0.00625	CcSEcCtD
Ethosuximide—Eye disorder—Cladribine—multiple sclerosis	0.000871	0.00618	CcSEcCtD
Ethosuximide—Euphoric mood—Prednisolone—multiple sclerosis	0.00086	0.0061	CcSEcCtD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000852	0.0192	CbGpPWpGaD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000852	0.0192	CbGpPWpGaD
Ethosuximide—Immune system disorder—Cladribine—multiple sclerosis	0.000842	0.00597	CcSEcCtD
Ethosuximide—Mediastinal disorder—Cladribine—multiple sclerosis	0.00084	0.00596	CcSEcCtD
Ethosuximide—Asthenia—Fingolimod—multiple sclerosis	0.000838	0.00594	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Azathioprine—multiple sclerosis	0.000837	0.00594	CcSEcCtD
Ethosuximide—Hiccups—Dexamethasone—multiple sclerosis	0.000835	0.00592	CcSEcCtD
Ethosuximide—Hiccups—Betamethasone—multiple sclerosis	0.000835	0.00592	CcSEcCtD
Ethosuximide—Mental disorder—Cladribine—multiple sclerosis	0.000816	0.00579	CcSEcCtD
Ethosuximide—Malnutrition—Cladribine—multiple sclerosis	0.000811	0.00575	CcSEcCtD
Ethosuximide—Abdominal pain upper—Mitoxantrone—multiple sclerosis	0.000809	0.00574	CcSEcCtD
Ethosuximide—Diarrhoea—Fingolimod—multiple sclerosis	0.000799	0.00567	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—CYP27B1—multiple sclerosis	0.000798	0.018	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—CYP24A1—multiple sclerosis	0.000798	0.018	CbGpPWpGaD
Ethosuximide—Euphoric mood—Triamcinolone—multiple sclerosis	0.000791	0.00561	CcSEcCtD
Ethosuximide—Euphoric mood—Methylprednisolone—multiple sclerosis	0.000789	0.0056	CcSEcCtD
Ethosuximide—Agranulocytosis—Azathioprine—multiple sclerosis	0.000788	0.00559	CcSEcCtD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000787	0.0178	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000787	0.0178	CbGpPWpGaD
Ethosuximide—Dizziness—Fingolimod—multiple sclerosis	0.000772	0.00548	CcSEcCtD
Ethosuximide—CYP3A5—Irinotecan Pathway—BCHE—multiple sclerosis	0.000752	0.017	CbGpPWpGaD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000746	0.0169	CbGpPWpGaD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000746	0.0169	CbGpPWpGaD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000737	0.0166	CbGpPWpGaD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000737	0.0166	CbGpPWpGaD
Ethosuximide—Headache—Fingolimod—multiple sclerosis	0.000732	0.00519	CcSEcCtD
Ethosuximide—Hiccups—Prednisone—multiple sclerosis	0.000727	0.00516	CcSEcCtD
Ethosuximide—Pancytopenia—Mitoxantrone—multiple sclerosis	0.000727	0.00516	CcSEcCtD
Ethosuximide—Euphoric mood—Betamethasone—multiple sclerosis	0.000717	0.00509	CcSEcCtD
Ethosuximide—Euphoric mood—Dexamethasone—multiple sclerosis	0.000717	0.00509	CcSEcCtD
Ethosuximide—Erythema multiforme—Azathioprine—multiple sclerosis	0.000716	0.00508	CcSEcCtD
Ethosuximide—Weight decreased—Mitoxantrone—multiple sclerosis	0.000692	0.00491	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000686	0.00487	CcSEcCtD
Ethosuximide—Immune system disorder—Azathioprine—multiple sclerosis	0.000684	0.00485	CcSEcCtD
Ethosuximide—Mediastinal disorder—Azathioprine—multiple sclerosis	0.000683	0.00484	CcSEcCtD
Ethosuximide—Drowsiness—Mitoxantrone—multiple sclerosis	0.000682	0.00484	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—CD24—multiple sclerosis	0.00067	0.0151	CbGpPWpGaD
Ethosuximide—Psychotic disorder—Methylprednisolone—multiple sclerosis	0.000651	0.00462	CcSEcCtD
Ethosuximide—Haematuria—Mitoxantrone—multiple sclerosis	0.000651	0.00461	CcSEcCtD
Ethosuximide—Nervous system disorder—Cladribine—multiple sclerosis	0.000649	0.00461	CcSEcCtD
Ethosuximide—Skin disorder—Cladribine—multiple sclerosis	0.000643	0.00456	CcSEcCtD
Ethosuximide—Agranulocytosis—Mitoxantrone—multiple sclerosis	0.000637	0.00452	CcSEcCtD
Ethosuximide—Irritability—Methylprednisolone—multiple sclerosis	0.000636	0.00451	CcSEcCtD
Ethosuximide—Hyperkinesia—Prednisone—multiple sclerosis	0.000634	0.0045	CcSEcCtD
Ethosuximide—Anorexia—Cladribine—multiple sclerosis	0.000631	0.00448	CcSEcCtD
Ethosuximide—Euphoric mood—Prednisone—multiple sclerosis	0.000625	0.00443	CcSEcCtD
Ethosuximide—Lethargy—Dexamethasone—multiple sclerosis	0.000619	0.00439	CcSEcCtD
Ethosuximide—Lethargy—Betamethasone—multiple sclerosis	0.000619	0.00439	CcSEcCtD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000605	0.0137	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000605	0.0137	CbGpPWpGaD
Ethosuximide—Breast disorder—Methylprednisolone—multiple sclerosis	0.000602	0.00427	CcSEcCtD
Ethosuximide—Psychotic disorder—Betamethasone—multiple sclerosis	0.000592	0.0042	CcSEcCtD
Ethosuximide—Psychotic disorder—Dexamethasone—multiple sclerosis	0.000592	0.0042	CcSEcCtD
Ethosuximide—Leukopenia—Azathioprine—multiple sclerosis	0.00059	0.00419	CcSEcCtD
Ethosuximide—Somnolence—Cladribine—multiple sclerosis	0.000589	0.00418	CcSEcCtD
Ethosuximide—Irritability—Betamethasone—multiple sclerosis	0.000579	0.0041	CcSEcCtD
Ethosuximide—Irritability—Dexamethasone—multiple sclerosis	0.000579	0.0041	CcSEcCtD
Ethosuximide—Decreased appetite—Cladribine—multiple sclerosis	0.000576	0.00408	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000572	0.00405	CcSEcCtD
Ethosuximide—Fatigue—Cladribine—multiple sclerosis	0.000571	0.00405	CcSEcCtD
Ethosuximide—Aplastic anaemia—Methotrexate—multiple sclerosis	0.000571	0.00405	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000558	0.00396	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000541	0.00384	CcSEcCtD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000541	0.0122	CbGpPWpGaD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000541	0.0122	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000539	0.0122	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000539	0.0122	CbGpPWpGaD
Ethosuximide—Lethargy—Prednisone—multiple sclerosis	0.000539	0.00382	CcSEcCtD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000533	0.0121	CbGpPWpGaD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000533	0.0121	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000532	0.012	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000532	0.012	CbGpPWpGaD
Ethosuximide—Urticaria—Cladribine—multiple sclerosis	0.000526	0.00373	CcSEcCtD
Ethosuximide—Abdominal pain—Cladribine—multiple sclerosis	0.000523	0.00371	CcSEcCtD
Ethosuximide—Skin disorder—Azathioprine—multiple sclerosis	0.000523	0.00371	CcSEcCtD
Ethosuximide—Psychotic disorder—Prednisone—multiple sclerosis	0.000516	0.00366	CcSEcCtD
Ethosuximide—Irritability—Prednisone—multiple sclerosis	0.000504	0.00357	CcSEcCtD
Ethosuximide—Hypersensitivity—Cladribine—multiple sclerosis	0.000488	0.00346	CcSEcCtD
Ethosuximide—Leukopenia—Mitoxantrone—multiple sclerosis	0.000477	0.00339	CcSEcCtD
Ethosuximide—Asthenia—Cladribine—multiple sclerosis	0.000475	0.00337	CcSEcCtD
Ethosuximide—Weight decreased—Betamethasone—multiple sclerosis	0.000474	0.00336	CcSEcCtD
Ethosuximide—Weight decreased—Dexamethasone—multiple sclerosis	0.000474	0.00336	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000465	0.0033	CcSEcCtD
Ethosuximide—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000453	0.00321	CcSEcCtD
Ethosuximide—Diarrhoea—Cladribine—multiple sclerosis	0.000453	0.00321	CcSEcCtD
Ethosuximide—Lethargy—Methotrexate—multiple sclerosis	0.00045	0.00319	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.00044	0.00312	CcSEcCtD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000438	0.0099	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000438	0.0099	CbGpPWpGaD
Ethosuximide—Dizziness—Cladribine—multiple sclerosis	0.000438	0.00311	CcSEcCtD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000437	0.00988	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000437	0.00988	CbGpPWpGaD
Ethosuximide—Eye disorder—Methylprednisolone—multiple sclerosis	0.000431	0.00306	CcSEcCtD
Ethosuximide—Abdominal pain—Azathioprine—multiple sclerosis	0.000426	0.00302	CcSEcCtD
Ethosuximide—Skin disorder—Mitoxantrone—multiple sclerosis	0.000423	0.003	CcSEcCtD
Ethosuximide—Irritability—Methotrexate—multiple sclerosis	0.000421	0.00299	CcSEcCtD
Ethosuximide—Vomiting—Cladribine—multiple sclerosis	0.000421	0.00299	CcSEcCtD
Ethosuximide—Rash—Cladribine—multiple sclerosis	0.000417	0.00296	CcSEcCtD
Ethosuximide—Dermatitis—Cladribine—multiple sclerosis	0.000417	0.00296	CcSEcCtD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000417	0.00942	CbGpPWpGaD
Ethosuximide—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000416	0.00295	CcSEcCtD
Ethosuximide—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000416	0.00295	CcSEcCtD
Ethosuximide—Anorexia—Mitoxantrone—multiple sclerosis	0.000415	0.00294	CcSEcCtD
Ethosuximide—Ataxia—Methotrexate—multiple sclerosis	0.000415	0.00294	CcSEcCtD
Ethosuximide—Headache—Cladribine—multiple sclerosis	0.000415	0.00294	CcSEcCtD
Ethosuximide—Weight decreased—Prednisone—multiple sclerosis	0.000413	0.00293	CcSEcCtD
Ethosuximide—Mental disorder—Methylprednisolone—multiple sclerosis	0.000404	0.00287	CcSEcCtD
Ethosuximide—Malnutrition—Methylprednisolone—multiple sclerosis	0.000401	0.00285	CcSEcCtD
Ethosuximide—Breast disorder—Methotrexate—multiple sclerosis	0.000399	0.00283	CcSEcCtD
Ethosuximide—Hypersensitivity—Azathioprine—multiple sclerosis	0.000397	0.00281	CcSEcCtD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000395	0.00893	CbGpPWpGaD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000395	0.00893	CbGpPWpGaD
Ethosuximide—Nausea—Cladribine—multiple sclerosis	0.000393	0.00279	CcSEcCtD
Ethosuximide—Eye disorder—Dexamethasone—multiple sclerosis	0.000392	0.00278	CcSEcCtD
Ethosuximide—Eye disorder—Betamethasone—multiple sclerosis	0.000392	0.00278	CcSEcCtD
Ethosuximide—Somnolence—Mitoxantrone—multiple sclerosis	0.000387	0.00274	CcSEcCtD
Ethosuximide—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000378	0.00268	CcSEcCtD
Ethosuximide—Eosinophilia—Methotrexate—multiple sclerosis	0.000378	0.00268	CcSEcCtD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—TYK2—multiple sclerosis	0.000376	0.0085	CbGpPWpGaD
Ethosuximide—Fatigue—Mitoxantrone—multiple sclerosis	0.000375	0.00266	CcSEcCtD
Ethosuximide—Diarrhoea—Azathioprine—multiple sclerosis	0.000368	0.00261	CcSEcCtD
Ethosuximide—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000366	0.00259	CcSEcCtD
Ethosuximide—Pancytopenia—Methotrexate—multiple sclerosis	0.000362	0.00257	CcSEcCtD
Ethosuximide—Connective tissue disorder—Prednisone—multiple sclerosis	0.000359	0.00255	CcSEcCtD
Ethosuximide—Dizziness—Azathioprine—multiple sclerosis	0.000356	0.00253	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000356	0.00252	CcSEcCtD
Ethosuximide—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00035	0.0079	CbGpPWpGaD
Ethosuximide—Urticaria—Mitoxantrone—multiple sclerosis	0.000346	0.00245	CcSEcCtD
Ethosuximide—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000344	0.00244	CcSEcCtD
Ethosuximide—Vomiting—Azathioprine—multiple sclerosis	0.000342	0.00243	CcSEcCtD
Ethosuximide—Eye disorder—Prednisone—multiple sclerosis	0.000341	0.00242	CcSEcCtD
Ethosuximide—Drowsiness—Methotrexate—multiple sclerosis	0.00034	0.00241	CcSEcCtD
Ethosuximide—Rash—Azathioprine—multiple sclerosis	0.000339	0.00241	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000339	0.00241	CcSEcCtD
Ethosuximide—Dermatitis—Azathioprine—multiple sclerosis	0.000339	0.00241	CcSEcCtD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000338	0.00764	CbGpPWpGaD
Ethosuximide—Headache—Azathioprine—multiple sclerosis	0.000337	0.00239	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000337	0.00239	CcSEcCtD
Ethosuximide—Immune system disorder—Prednisone—multiple sclerosis	0.00033	0.00234	CcSEcCtD
Ethosuximide—Haematuria—Methotrexate—multiple sclerosis	0.000324	0.0023	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—CYP24A1—multiple sclerosis	0.000321	0.00726	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—CYP27B1—multiple sclerosis	0.000321	0.00726	CbGpPWpGaD
Ethosuximide—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000321	0.00228	CcSEcCtD
Ethosuximide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000321	0.00227	CcSEcCtD
Ethosuximide—Mental disorder—Prednisone—multiple sclerosis	0.00032	0.00227	CcSEcCtD
Ethosuximide—Nausea—Azathioprine—multiple sclerosis	0.00032	0.00227	CcSEcCtD
Ethosuximide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000318	0.00226	CcSEcCtD
Ethosuximide—Malnutrition—Prednisone—multiple sclerosis	0.000318	0.00225	CcSEcCtD
Ethosuximide—Agranulocytosis—Methotrexate—multiple sclerosis	0.000317	0.00225	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000317	0.00716	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000317	0.00716	CbGpPWpGaD
Ethosuximide—Asthenia—Mitoxantrone—multiple sclerosis	0.000312	0.00221	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—PRNP—multiple sclerosis	0.00031	0.007	CbGpPWpGaD
Ethosuximide—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000301	0.00214	CcSEcCtD
Ethosuximide—Urethral disorder—Methotrexate—multiple sclerosis	0.000299	0.00212	CcSEcCtD
Ethosuximide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000298	0.00211	CcSEcCtD
Ethosuximide—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000292	0.00207	CcSEcCtD
Ethosuximide—Nervous system disorder—Betamethasone—multiple sclerosis	0.000292	0.00207	CcSEcCtD
Ethosuximide—Agitation—Prednisone—multiple sclerosis	0.000292	0.00207	CcSEcCtD
Ethosuximide—Erythema multiforme—Methotrexate—multiple sclerosis	0.000289	0.00205	CcSEcCtD
Ethosuximide—Eye disorder—Methotrexate—multiple sclerosis	0.000285	0.00202	CcSEcCtD
Ethosuximide—Anorexia—Betamethasone—multiple sclerosis	0.000284	0.00201	CcSEcCtD
Ethosuximide—Anorexia—Dexamethasone—multiple sclerosis	0.000284	0.00201	CcSEcCtD
Ethosuximide—Urticaria—Prednisolone—multiple sclerosis	0.000284	0.00201	CcSEcCtD
Ethosuximide—Fatigue—Triamcinolone—multiple sclerosis	0.000283	0.00201	CcSEcCtD
Ethosuximide—Fatigue—Methylprednisolone—multiple sclerosis	0.000282	0.002	CcSEcCtD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000279	0.0063	CbGpPWpGaD
Ethosuximide—Vomiting—Mitoxantrone—multiple sclerosis	0.000277	0.00196	CcSEcCtD
Ethosuximide—Immune system disorder—Methotrexate—multiple sclerosis	0.000276	0.00196	CcSEcCtD
Ethosuximide—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000275	0.00195	CcSEcCtD
Ethosuximide—Rash—Mitoxantrone—multiple sclerosis	0.000274	0.00195	CcSEcCtD
Ethosuximide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000274	0.00194	CcSEcCtD
Ethosuximide—Headache—Mitoxantrone—multiple sclerosis	0.000273	0.00193	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000269	0.00191	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000268	0.0019	CcSEcCtD
Ethosuximide—Mental disorder—Methotrexate—multiple sclerosis	0.000267	0.0019	CcSEcCtD
Ethosuximide—Malnutrition—Methotrexate—multiple sclerosis	0.000266	0.00188	CcSEcCtD
Ethosuximide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000263	0.00187	CcSEcCtD
Ethosuximide—Urticaria—Triamcinolone—multiple sclerosis	0.000261	0.00185	CcSEcCtD
Ethosuximide—Urticaria—Methylprednisolone—multiple sclerosis	0.00026	0.00185	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—multiple sclerosis	0.00026	0.00587	CbGpPWpGaD
Ethosuximide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000259	0.00184	CcSEcCtD
Ethosuximide—Decreased appetite—Betamethasone—multiple sclerosis	0.000259	0.00184	CcSEcCtD
Ethosuximide—Decreased appetite—Dexamethasone—multiple sclerosis	0.000259	0.00184	CcSEcCtD
Ethosuximide—Nausea—Mitoxantrone—multiple sclerosis	0.000258	0.00183	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000257	0.00182	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000257	0.00182	CcSEcCtD
Ethosuximide—Fatigue—Dexamethasone—multiple sclerosis	0.000257	0.00182	CcSEcCtD
Ethosuximide—Fatigue—Betamethasone—multiple sclerosis	0.000257	0.00182	CcSEcCtD
Ethosuximide—Nervous system disorder—Prednisone—multiple sclerosis	0.000254	0.0018	CcSEcCtD
Ethosuximide—Skin disorder—Prednisone—multiple sclerosis	0.000252	0.00179	CcSEcCtD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000251	0.00567	CbGpPWpGaD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000251	0.00567	CbGpPWpGaD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000248	0.00559	CbGpPWpGaD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000248	0.00559	CbGpPWpGaD
Ethosuximide—Anorexia—Prednisone—multiple sclerosis	0.000247	0.00175	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000244	0.00173	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000244	0.00173	CcSEcCtD
Ethosuximide—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000242	0.00172	CcSEcCtD
Ethosuximide—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000241	0.00171	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—PTPRC—multiple sclerosis	0.000241	0.00545	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—MAPK1—multiple sclerosis	0.000239	0.00541	CbGpPWpGaD
Ethosuximide—Leukopenia—Methotrexate—multiple sclerosis	0.000238	0.00169	CcSEcCtD
Ethosuximide—Urticaria—Dexamethasone—multiple sclerosis	0.000237	0.00168	CcSEcCtD
Ethosuximide—Urticaria—Betamethasone—multiple sclerosis	0.000237	0.00168	CcSEcCtD
Ethosuximide—Dizziness—Prednisolone—multiple sclerosis	0.000236	0.00167	CcSEcCtD
Ethosuximide—Asthenia—Triamcinolone—multiple sclerosis	0.000236	0.00167	CcSEcCtD
Ethosuximide—Abdominal pain—Betamethasone—multiple sclerosis	0.000236	0.00167	CcSEcCtD
Ethosuximide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000236	0.00167	CcSEcCtD
Ethosuximide—Asthenia—Methylprednisolone—multiple sclerosis	0.000235	0.00167	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—CYP27B1—multiple sclerosis	0.000233	0.00526	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—CYP24A1—multiple sclerosis	0.000233	0.00526	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000232	0.00525	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000232	0.00525	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00023	0.00519	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00023	0.00519	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000229	0.00518	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000229	0.00518	CbGpPWpGaD
Ethosuximide—Decreased appetite—Prednisone—multiple sclerosis	0.000226	0.0016	CcSEcCtD
Ethosuximide—Rash—Prednisolone—multiple sclerosis	0.000225	0.0016	CcSEcCtD
Ethosuximide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000225	0.00509	CbGpPWpGaD
Ethosuximide—Dermatitis—Prednisolone—multiple sclerosis	0.000225	0.0016	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000225	0.00159	CcSEcCtD
Ethosuximide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000224	0.00159	CcSEcCtD
Ethosuximide—Fatigue—Prednisone—multiple sclerosis	0.000224	0.00159	CcSEcCtD
Ethosuximide—Headache—Prednisolone—multiple sclerosis	0.000224	0.00159	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—PRNP—multiple sclerosis	0.000221	0.005	CbGpPWpGaD
Ethosuximide—Dizziness—Triamcinolone—multiple sclerosis	0.000217	0.00154	CcSEcCtD
Ethosuximide—Dizziness—Methylprednisolone—multiple sclerosis	0.000217	0.00154	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—multiple sclerosis	0.000215	0.00485	CbGpPWpGaD
Ethosuximide—Asthenia—Dexamethasone—multiple sclerosis	0.000214	0.00152	CcSEcCtD
Ethosuximide—Asthenia—Betamethasone—multiple sclerosis	0.000214	0.00152	CcSEcCtD
Ethosuximide—Nervous system disorder—Methotrexate—multiple sclerosis	0.000213	0.00151	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000212	0.0015	CcSEcCtD
Ethosuximide—Nausea—Prednisolone—multiple sclerosis	0.000212	0.0015	CcSEcCtD
Ethosuximide—Skin disorder—Methotrexate—multiple sclerosis	0.000211	0.00149	CcSEcCtD
Ethosuximide—Vomiting—Triamcinolone—multiple sclerosis	0.000209	0.00148	CcSEcCtD
Ethosuximide—Vomiting—Methylprednisolone—multiple sclerosis	0.000208	0.00148	CcSEcCtD
Ethosuximide—Rash—Triamcinolone—multiple sclerosis	0.000207	0.00147	CcSEcCtD
Ethosuximide—Dermatitis—Triamcinolone—multiple sclerosis	0.000207	0.00147	CcSEcCtD
Ethosuximide—Anorexia—Methotrexate—multiple sclerosis	0.000207	0.00147	CcSEcCtD
Ethosuximide—Rash—Methylprednisolone—multiple sclerosis	0.000207	0.00147	CcSEcCtD
Ethosuximide—Dermatitis—Methylprednisolone—multiple sclerosis	0.000206	0.00146	CcSEcCtD
Ethosuximide—Urticaria—Prednisone—multiple sclerosis	0.000206	0.00146	CcSEcCtD
Ethosuximide—Headache—Triamcinolone—multiple sclerosis	0.000206	0.00146	CcSEcCtD
Ethosuximide—Headache—Methylprednisolone—multiple sclerosis	0.000205	0.00146	CcSEcCtD
Ethosuximide—Abdominal pain—Prednisone—multiple sclerosis	0.000205	0.00145	CcSEcCtD
Ethosuximide—Diarrhoea—Betamethasone—multiple sclerosis	0.000204	0.00145	CcSEcCtD
Ethosuximide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000204	0.00145	CcSEcCtD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000203	0.0046	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000203	0.0046	CbGpPWpGaD
Ethosuximide—Dizziness—Betamethasone—multiple sclerosis	0.000197	0.0014	CcSEcCtD
Ethosuximide—Dizziness—Dexamethasone—multiple sclerosis	0.000197	0.0014	CcSEcCtD
Ethosuximide—Nausea—Triamcinolone—multiple sclerosis	0.000195	0.00138	CcSEcCtD
Ethosuximide—Nausea—Methylprednisolone—multiple sclerosis	0.000195	0.00138	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—SRM—multiple sclerosis	0.000194	0.00438	CbGpPWpGaD
Ethosuximide—Somnolence—Methotrexate—multiple sclerosis	0.000193	0.00137	CcSEcCtD
Ethosuximide—Hypersensitivity—Prednisone—multiple sclerosis	0.000191	0.00136	CcSEcCtD
Ethosuximide—Vomiting—Betamethasone—multiple sclerosis	0.000189	0.00134	CcSEcCtD
Ethosuximide—Vomiting—Dexamethasone—multiple sclerosis	0.000189	0.00134	CcSEcCtD
Ethosuximide—Decreased appetite—Methotrexate—multiple sclerosis	0.000188	0.00134	CcSEcCtD
Ethosuximide—Rash—Dexamethasone—multiple sclerosis	0.000188	0.00133	CcSEcCtD
Ethosuximide—Rash—Betamethasone—multiple sclerosis	0.000188	0.00133	CcSEcCtD
Ethosuximide—Dermatitis—Betamethasone—multiple sclerosis	0.000188	0.00133	CcSEcCtD
Ethosuximide—Dermatitis—Dexamethasone—multiple sclerosis	0.000188	0.00133	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000187	0.00133	CcSEcCtD
Ethosuximide—Fatigue—Methotrexate—multiple sclerosis	0.000187	0.00133	CcSEcCtD
Ethosuximide—Headache—Betamethasone—multiple sclerosis	0.000187	0.00132	CcSEcCtD
Ethosuximide—Headache—Dexamethasone—multiple sclerosis	0.000187	0.00132	CcSEcCtD
Ethosuximide—Asthenia—Prednisone—multiple sclerosis	0.000186	0.00132	CcSEcCtD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—multiple sclerosis	0.000184	0.00415	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—POMC—multiple sclerosis	0.000179	0.00406	CbGpPWpGaD
Ethosuximide—Diarrhoea—Prednisone—multiple sclerosis	0.000178	0.00126	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000177	0.00126	CcSEcCtD
Ethosuximide—Nausea—Betamethasone—multiple sclerosis	0.000177	0.00126	CcSEcCtD
Ethosuximide—Nausea—Dexamethasone—multiple sclerosis	0.000177	0.00126	CcSEcCtD
Ethosuximide—Urticaria—Methotrexate—multiple sclerosis	0.000172	0.00122	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—PTPRC—multiple sclerosis	0.000172	0.00389	CbGpPWpGaD
Ethosuximide—Dizziness—Prednisone—multiple sclerosis	0.000172	0.00122	CcSEcCtD
Ethosuximide—Abdominal pain—Methotrexate—multiple sclerosis	0.000171	0.00122	CcSEcCtD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000168	0.00379	CbGpPWpGaD
Ethosuximide—Vomiting—Prednisone—multiple sclerosis	0.000165	0.00117	CcSEcCtD
Ethosuximide—Rash—Prednisone—multiple sclerosis	0.000164	0.00116	CcSEcCtD
Ethosuximide—Dermatitis—Prednisone—multiple sclerosis	0.000163	0.00116	CcSEcCtD
Ethosuximide—Headache—Prednisone—multiple sclerosis	0.000163	0.00115	CcSEcCtD
Ethosuximide—Hypersensitivity—Methotrexate—multiple sclerosis	0.00016	0.00113	CcSEcCtD
Ethosuximide—Asthenia—Methotrexate—multiple sclerosis	0.000156	0.0011	CcSEcCtD
Ethosuximide—Nausea—Prednisone—multiple sclerosis	0.000154	0.00109	CcSEcCtD
Ethosuximide—Diarrhoea—Methotrexate—multiple sclerosis	0.000148	0.00105	CcSEcCtD
Ethosuximide—Dizziness—Methotrexate—multiple sclerosis	0.000143	0.00102	CcSEcCtD
Ethosuximide—Vomiting—Methotrexate—multiple sclerosis	0.000138	0.000978	CcSEcCtD
Ethosuximide—Rash—Methotrexate—multiple sclerosis	0.000137	0.00097	CcSEcCtD
Ethosuximide—Dermatitis—Methotrexate—multiple sclerosis	0.000137	0.000969	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—CYP27B1—multiple sclerosis	0.000136	0.00308	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CYP24A1—multiple sclerosis	0.000136	0.00308	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000136	0.00308	CbGpPWpGaD
Ethosuximide—Headache—Methotrexate—multiple sclerosis	0.000136	0.000964	CcSEcCtD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000129	0.00292	CbGpPWpGaD
Ethosuximide—Nausea—Methotrexate—multiple sclerosis	0.000129	0.000914	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—GPC5—multiple sclerosis	0.000125	0.00282	CbGpPWpGaD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000122	0.00275	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000121	0.00274	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000108	0.00244	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000108	0.00244	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—TYK2—multiple sclerosis	0.000108	0.00244	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000107	0.00241	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000107	0.00241	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—RRM1—multiple sclerosis	0.000103	0.00234	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.86e-05	0.00223	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.84e-05	0.00222	CbGpPWpGaD
Ethosuximide—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	8.98e-05	0.00203	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MMP9—multiple sclerosis	8.49e-05	0.00192	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—SRM—multiple sclerosis	7.8e-05	0.00176	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TYK2—multiple sclerosis	7.69e-05	0.00174	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—POMC—multiple sclerosis	7.23e-05	0.00163	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MAPK1—multiple sclerosis	6.86e-05	0.00155	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MMP9—multiple sclerosis	6.06e-05	0.00137	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—BCHE—multiple sclerosis	5.94e-05	0.00134	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—SRM—multiple sclerosis	5.65e-05	0.00128	CbGpPWpGaD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.64e-05	0.00128	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—SRM—multiple sclerosis	5.64e-05	0.00127	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	5.5e-05	0.00124	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	5.5e-05	0.00124	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—STAT3—multiple sclerosis	5.39e-05	0.00122	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—IL6—multiple sclerosis	5.27e-05	0.00119	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—POMC—multiple sclerosis	5.24e-05	0.00118	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—POMC—multiple sclerosis	5.23e-05	0.00118	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GPC5—multiple sclerosis	5.03e-05	0.00114	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TGFB1—multiple sclerosis	4.99e-05	0.00113	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MAPK1—multiple sclerosis	4.9e-05	0.00111	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TNF—multiple sclerosis	4.66e-05	0.00105	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.57e-05	0.00103	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—RRM1—multiple sclerosis	4.17e-05	0.000941	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP27B1—multiple sclerosis	3.98e-05	0.0009	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP24A1—multiple sclerosis	3.98e-05	0.0009	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	3.97e-05	0.000898	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	3.97e-05	0.000898	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—IL6—multiple sclerosis	3.76e-05	0.00085	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GPC5—multiple sclerosis	3.64e-05	0.000823	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GPC5—multiple sclerosis	3.63e-05	0.000821	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—APOE—multiple sclerosis	3.57e-05	0.000808	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—POMC—multiple sclerosis	3.07e-05	0.000694	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—RRM1—multiple sclerosis	3.02e-05	0.000682	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—RRM1—multiple sclerosis	3.01e-05	0.00068	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ALB—multiple sclerosis	2.8e-05	0.000632	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—SRM—multiple sclerosis	2.62e-05	0.000592	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.43e-05	0.000549	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—BCHE—multiple sclerosis	2.39e-05	0.000541	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.85e-05	0.000417	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.85e-05	0.000417	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—BCHE—multiple sclerosis	1.73e-05	0.000392	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.73e-05	0.000391	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.69e-05	0.000382	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—APOE—multiple sclerosis	1.44e-05	0.000325	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.4e-05	0.000316	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—POMC—multiple sclerosis	1.24e-05	0.000279	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ALB—multiple sclerosis	1.13e-05	0.000255	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—APOE—multiple sclerosis	1.04e-05	0.000236	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—APOE—multiple sclerosis	1.04e-05	0.000235	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—POMC—multiple sclerosis	8.96e-06	0.000202	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—POMC—multiple sclerosis	8.94e-06	0.000202	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ALB—multiple sclerosis	8.16e-06	0.000185	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ALB—multiple sclerosis	8.15e-06	0.000184	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—BCHE—multiple sclerosis	8.04e-06	0.000182	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—APOE—multiple sclerosis	4.84e-06	0.000109	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—POMC—multiple sclerosis	4.15e-06	9.39e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ALB—multiple sclerosis	3.79e-06	8.56e-05	CbGpPWpGaD
